A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf
.
Characteristics of Rapamycin-treated T cell products for advanced adoptive T cell therapy and evaluation of clinical feasibility
[thesis]
2020
The requirement for long-term immunosuppression to prevent rejections predisposes solid organ transplant recipients to severe or fatal viral complications, e.g. caused by cytomegalovirus (CMV). Classical antiviral medication is often problematic or ineffective. Hence, virus-specific adoptive T cell therapy emerged as attractive therapeutic option for viral diseases occurring after transplantation. Despite clinical safety of antiviral T cell products (TCPs) and impressive initial effectiveness,
doi:10.17169/refubium-27688
fatcat:jfpb27gqgbfhlhlk4s25ciphzm